Die Therapie von Tumorrezidiven bzw. Zweitkarzinomen in vorbehandeltem Gebiet ist nicht mit der Primärtherapie in nicht-vorbehandeltem Gewebe gleichzusetzen – eine Übersicht

Andreas Dietz; S. Wiegand; H. Bläker; W. Budach

doi:10.1055/a-2287-2280

TumorDiagnostik & Therapie, Table of Contents

TumorDiagnostik & Therapie 2024; 45(04): 243-250
DOI: 10.1055/a-2287-2280

Thieme Onkologie aktuell

Die Therapie von Tumorrezidiven bzw. Zweitkarzinomen in vorbehandeltem Gebiet ist nicht mit der Primärtherapie in nicht-vorbehandeltem Gewebe gleichzusetzen – eine Übersicht

Therapy of tumor recurrences or secondary carcinomas in pretreated area is not compatible with the primary therapy in non-previously treated tissue – an overview

Authors

Andreas Dietz

¹Hals-Nasen-Ohren-Universitätsklinik, Leipzig
S. Wiegand

¹Hals-Nasen-Ohren-Universitätsklinik, Leipzig
H. Bläker

²Institut für Pathologie, Universität Leipzig
W. Budach

³Klinik für Strahlentherapie und Radioonkologie, Universität Düsseldorf

Abstract

Zusammenfassung

Bei der Behandlung von lokalen bzw. lokoregionären Rezidiven, Zweitkarzinomen oder Residuen von Plattenepithelkarzinomen der Kopf-Hals-Region nach einer Primärtherapie ergeben sich unterschiedliche Ausgangsituationen. Bei der Mehrzahl der Patienten mit lokoregionären Rezidiven ist eine Vorbehandlung bestehend aus Operation und/oder postoperativer Radio- bzw. Radiochemotherapie oder eine primäre Radio- bzw. Radiochemotherapie erfolgt. In jedem Fall handelt es sich um ein erneutes Tumorwachstum in vorbehandeltem Gebiet, das in besonderer Weise für die Therapieentscheidung berücksichtigt werden muss. Die biologischen Hintergründe sind vielfältig und werden in der vorliegenden Arbeit näher beschrieben und klinisch eingeordnet.

Abstract

There are different initial situations in the treatment of local or locoregional recurrences, secondary carcinomas or residual squamous cell carcinomas of the head and neck region after primary therapy. The majority of patients with locoregional recurrences have had prior treatment consisting of surgery and/or postoperative radiotherapy or radiochemotherapy or primary radiotherapy or radiochemotherapy. In any case, it is a matter of new tumor growth in a previously treated area, which must be taken into account for the therapy decision. The biological backgrounds are diverse and are described in more detail and clinically classified in the present work.

Schlüsselwörter

Rezidivtherapie - Kopf-Hals-Karzinom - Plattenepithelkarzinom Kopf-Hals - Rebestrahlung - Salvage-Chirurgie

Keywords

recurrence therapy - head and neck carcinoma - squamous cell carcinoma head and neck - re-irradiation - salvage surgery

Full Text

References

Literatur
1 Leith JT, Michelson S. Tumor radiocurability: relationship to intrinsic tumor heterogeneity and to the tumor bed effect. Invasion Metastasis 1990; 10 (06) 329-351
2 Milas L, Hunter N, Peters LJ. The tumor bed effect: dependence of tumor take, growth rate, and metastasis on the time interval between irradiation and tumor cell transplantation. Int J Radiat Oncol Biol Phys 1987; 13 (03) 379-383
3 Haveman J. et al. Residual late radiation damage in mouse stromal tissue assessed by the tumor bed effect. J Radiat Res 2007; 48 (02) 107-112
4 Milas L. et al. Effect of radiation-induced injury of tumor bed stroma on metastatic spread of murine sarcomas and carcinomas. Cancer Res 1988; 48 (08) 2116-2120
5 Ang KK. et al. Extent and kinetics of recovery of occult spinal cord injury. Int J Radiat Oncol Biol Phys 2001; 50 (04) 1013-1020
6 Zbären P, Nuyens M, Curschmann J. et al. Histologic characteristics and tumor spread of recurrent glottic carcinoma: analysis on whole-organ sections and comparison with tumor spread of primary glottic carcinomas. Head Neck 2007; 29 (01) 26-32
7 Lee HJ, Jang YJ. Recent Understandings of Biology, Prophylaxis and Treatment Strategies for Hypertrophic Scars and Keloids. Int J Mol Sci 2018; 19 (03) 711
8 Ueda K. et al. Inadequate blood supply persists in keloids. Scand J Plast Reconstr Surg Hand Surg 2004; 38 (05) 267-271
9 Zhao B. et al. Hypoxia drives the transition of human dermal fibroblasts to a myofibroblast-like phenotype via the TGF-β1/Smad3 pathway. Int J Mol Med 2017; 39 (01) 153-159
10 Zafereo M. Surgical salvage of recurrent cancer of the head and neck. Curr Oncol Rep 2014; 16 (05) 386
11 Mandapathil M. et al. Salvage surgery for head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol 2014; 271 (07) 1845-1850
12 Goodwin WJ. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means?. Laryngoscope 2000; 110 (03) 1-18
13 Sanabria A. et al. Salvage surgery for head and neck cancer: a plea for better definitions. Eur Arch Otorhinolaryngol 2014; 271 (06) 1347-1350
14 Bots WTC. et al. Reirradiation of head and neck cancer: Long-term disease control and toxicity. Head Neck 2017; 39 (06) 1122-1130
15 Ward MC. et al. Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative. Int J Radiat Oncol Biol Phys 2018; 100 (03) 586-594
16 Vargo JA. et al. A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer. Int J Radiat Oncol Biol Phys 2018; 100 (03) 595-605
17 Caudell JJ. et al. NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022. J Natl Compr Canc Netw 2022; 20 (03) 224-234
18 Choi SH. et al. Re-irradiation Using Intensity-modulated Radiotherapy for Recurrent and Second Primary Head and Neck Cancer. Anticancer Res 2018; 38 (05) 3165-3173
19 Machiels JP. et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020; 31 (11) 1462-1475
20 Lee J. et al. Reirradiation with intensity-modulated radiation therapy for recurrent or secondary head and neck cancer: Meta-analysis and systematic review. Head Neck 2020; 42 (09) 2473-2485
21 Kao SS, Ooi EH. Survival outcomes following salvage surgery for oropharyngeal squamous cell carcinoma: systematic review. J Laryngol Otol 2018; 132 (04) 299-313
22 Philouze P, Péron J, Poupart M. et al. Salvage surgery for oropharyngeal squamous cell carcinomas: A retrospective study from 2005 to 2013. Head Neck 2017; 39 (09) 1744-1750
23 Chung EJ. et al. Clinical outcome and prognostic factors after salvage surgery for isolated regional squamous cell carcinoma recurrences. Head Neck 2015; 37 (11) 1612-1617
24 Jayaram SC. et al. Efficacy, outcomes, and complication rates of different surgical and nonsurgical treatment modalities for recurrent/residual oropharyngeal carcinoma: A systematic review and meta-analysis. Head Neck 2016; 38 (12) 1855-1861
25 Joseph AW. et al. Disease-free survival after salvage therapy for recurrent oropharyngeal squamous cell carcinoma. Head Neck 2016; 38 (Suppl. 01) E1501-E1509
26 Guo T. et al. Surgical salvage improves overall survival for patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer. Cancer 2015; 121 (12) 1977-1984
27 Zafereo ME. et al. The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer 2009; 115 (24) 5723-5733
28 Patel SN. et al. Salvage surgery for locally recurrent oropharyngeal cancer. Head Neck 2016; 38 (Suppl. 01) E658-E664
29 Nakamoto Y. et al. Clinical value of image fusion from MR and PET in patients with head and neck cancer. Mol Imaging Biol 2009; 11 (01) 46-53
30 Mehanna H. et al. PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. N Engl J Med 2016; 374 (15) 1444-1454
31 S3-Leitlinie Diagnostik, Therapie und Nachsorge des Larynxkarzinoms. Langversion 1.1, AWMF-Registernummer: 017/076OL. 2019 https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Larynxkarzinom/Version1.1/LL_Larynxkarzinom_Langversion_1.1.pdf
32 Kwon D. et al. Overcoming wound complications in head and neck salvage surgery. Auris Nasus Larynx 2018; 45 (06) 1135-1142
33 Dequanter D. et al. The effect of hyperbaric oxygen therapy on treatment of wound complications after oral, pharyngeal and laryngeal salvage surgery. Undersea Hyperb Med 2013; 40 (05) 381-385
34 Reiter M, Harréus U. Vacuum assisted closure in the management of wound healing disorders in the head and neck: a retrospective analysis of 23 cases. Am J Otolaryngol 2013; 34 (05) 411-415
35 Fung K. et al. Prevention of wound complications following salvage laryngectomy using free vascularized tissue. Head Neck 2007; 29 (05) 425-430
36 Yeh DH, Sahovaler A, Fung K. Reconstruction after salvage laryngectomy. Oral Oncol 2017; 75: 22-27
37 Baek CH. et al. Free flap outcome of salvage surgery compared to primary surgery for head and neck defects: A propensity score analysis. Oral Oncol 2016; 62: 85-89
38 Khan NA. et al. Fistula rates after salvage laryngectomy: comparing pectoralis myofascial and myocutaneous flaps. Laryngoscope 2014; 124 (07) 1615-1617
39 Patel UA. et al. Impact of pharyngeal closure technique on fistula after salvage laryngectomy. JAMA Otolaryngol Head Neck Surg 2013; 139 (11) 1156-1162
40 Shah JP. Patterns of cervical lymph node metastasis from squamous carcinomas of the upper aerodigestive tract. Am J Surg 1990; 160 (04) 405-409
41 Paleri V. et al. Vascularized tissue to reduce fistula following salvage total laryngectomy: a systematic review. Laryngoscope 2014; 124 (08) 1848-1853
42 Sayles M, Grant DG. Preventing pharyngo-cutaneous fistula in total laryngectomy: a systematic review and meta-analysis. Laryngoscope 2014; 124 (05) 1150-1163
43 Schwaab G. et al. Surgical salvage treatment of T1 / T2 glottic carcinoma after failure of radiotherapy. Am J Surg 1994; 168 (05) 474-475
44 Putten L. et al. Salvage surgery in post-chemoradiation laryngeal and hypopharyngeal carcinoma: outcome and review. Acta Otorhinolaryngol Ital 2015; 35 (03) 162-172
45 Janot F. et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008; 26 (34) 5518-5523
46 Dionisi F. et al. Organs at risk's tolerance and dose limits for head and neck cancer re-irradiation: A literature review. Oral Oncol 2019; 98: 35-47
47 Rühle A. et al. The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer. Radiat Oncol 2020; 15 (01) 81
48 Caudell JJ. et al. Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis. Int J Radiat Oncol Biol Phys 2018; 100 (03) 606-617
49 Lee A. et al. Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma. JAMA Netw Open 2023; 6 (01) e2250607
50 Kreinbrink PJ. et al. Reirradiation of Recurrent and Second Primary Cancers of the Head and Neck: a Review of the Contemporary Evidence. Curr Treat Options Oncol 2022; 23 (03) 295-310
51 Dionisi F. et al. Organs at risk's tolerance and dose limits for head and neck cancer re-irradiation: A literature review. Oral Oncol 2019; 98: 35-47
52 Yamazaki H. et al. Carotid blowout syndrome in pharyngeal cancer patients treated by hypofractionated stereotactic re-irradiation using CyberKnife: A multi-institutional matched-cohort analysis. Radiother Oncol 2015; 115 (01) 67-71
53 Ohizumi Y. et al. Complications following re-irradiation for head and neck cancer. Am J Otolaryngol 2002; 23 (04) 215-221
54 Ward MC. et al. Retreatment of Recurrent or Second Primary Head and Neck Cancer After Prior Radiation: Executive Summary of the American Radium Society Appropriate Use Criteria. Int J Radiat Oncol Biol Phys 2022; 113 (04) 759-786
55 Akbaba S. et al. Salvage radiotherapy for recurrent hypopharyngeal and laryngeal squamous cell carcinoma (SCC) after first-line treatment with surgery alone: a 10-year single-centre experience. Radiat Oncol 2019; 14 (01) 34